Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues. 

China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.

Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.

In this mixed Chinese- and English-language episode, guest speaker Treehill Partners co-founder Ali Pashadezah joins Brian Yang and Dexter Yan to discuss updates on the proposed BIOSECURE Act in the US Congress and US-China biotech movements. Also discussed is how Chinese biotechs are becoming acquisition targets for overseas biotech companies, including the recent purchases of Profound by Genmab and AnHeart Theraputics by Nuvantion.

The potential impact of the BIOSECURE Act continues to spread as the Biden administration increases its focus on China. But with BIO's top lobbyist and the top House sponsor of the legislation now headed out the door, the future of the bill remains uncertain.

A newly enacted regulation in China governing the overseas transfer of data allows waivers under certain conditions but also introduces some new hurdles compared to the draft version.